Avidity Biosciences to be Acquired by Novartis
Avidity Biosciences, which is developing an exon 44 skipping therapy for Duchenne muscular dystrophy, announced that it has entered into a definitive merger agreement...
A Statement from NorthStar Network on Givinostat (Duvyzat)
According to an announcement on the Muscular Dystrophy UK website, NorthStar Network stated: 'As part of ongoing surveillance of the risk profile of Givinostat...
Aji Bio-Pharma and Gene Tools LLC Announce Collaboration for Duchenne Muscular Dystrophy (DMD)
Aji Bio-Pharma a leading provider of biopharmaceutical contract development and manufacturing services, and Gene Tools LLC announced a formal collaboration to broaden access to...
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy
Satellos Bioscience, announced that the first patient has been dosed in the open-label, long-term follow-up study (LT-001) of SAT-3247 in adult males with Duchenne...
Brogidirsen (NS-089/NCNP-02) has The Potential to Slow Disease Progression in DMD Patients Amenable to Exon 44 Skipping
Nippon Shinyaku announced efficacy and safety data from a 3.5-year application based on an open-label extension study that also included the initiation of a...